View Programme

Book Now


HSJ Life Sciences Forum
Innovating to deliver improved patient services and outcomes

BMA House, London • 4 June 2019


08:45 Registration and refreshments

Chair’s opening remarks

Oli Hudson, Content Director, Wilmington Healthcare 



Assessing risks and opportunities of the Life Sciences Industrial Strategy

  • Gain insight into the progress of the Life Sciences Industrial Strategy two years down the line
  • Come face to face with senior leaders and have your chance to challenge the implementation of the Strategy
  • Find out what is being done to speed up market access in the NHS


Adapting your value proposition to align with integrated care models

  • Hear from frontline NHS leaders on how they are developing Integrated Care Systems and understand what opportunities there are for pharma to contribute to their development
  • Find out specific details about Integrated Care Provider Contracts and learn how commercial priorities may change as a result
  • Learn why you need to reshape your value proposition across the entire healthcare ecosystem and align with key principles that underpin the NHS Long Term Plan to become more commercially attractive 


Shifting from supplier to partner: Strengthening collaboration between pharma and the NHS 

  • Understand what you can do to meet the needs of your NHS customers
  • Get practical insight and specific strategies for enhancing engagement with the key stakeholders
  • Hear successful examples of new, collaborative ways of working between pharma and the NHS

Morning refreshments and networking


Interactive Discussion Groups

Address pertinent areas of interest and challenges in a pre-selected discussion group hosted by subject experts. To finish, all delegates will re-group and session leaders will share key takeaways discussed at their table.

With groups limited to 12 participants per table, ensure you sign up early to secure your place.

1) Aligning industry initiatives with population health ​

2) Following the money: Decision making processes of NHS financial flows ​

3) Identifying stakeholders and navigating Primary Care Networks ​

4) Engaging with impact for true market access

James Roach, Director of West Essex One Health and Care Partnership and Founder of Conclusio ​


Networking Lunch


Stream A: Data and digital

Chaired by Oli Hudson, Content Director, Wilmington Healthcare 

Stream B: Regulatory bodies

Chaired by Steve How, Programme Director, Wilmington Healthcare 



Going beyond the pill: Pharma’s role in the NHS’s vision for a digital future 

  • Find out what opportunities there are for pharma in the NHS digital agenda 
  • Hear about one organisation’s successful efforts to digitise operations and what benefits they’ve found as a result 
  • Discuss the main challenges of bringing technology into pharma and how you can tackle them  


The AHSN innovation exchange: Sharing learning and best practice 

  • Hear recent examples of innovations that have been rolled out at pace and scale within the NHS 
  • Find out what the NHS requires from pharma and what type of innovations are encouraged
  • Gain insight into the strategies put in place to ensure validated innovations are actually adopted  


Life Sciences 4.0: Harnessing data to secure future value and accelerate business impact in the digital landscape

  • Gain insight into the role data will play in your business, with products no longer being the central driver of value
  • Find out why you need to adopt a flexible business model and invest strategically in capabilities to accommodate the development of data driven health outcomes
  • Learn how you can capture sustainable future value and position your business as a leader in this new industry paradigm 


Future proofing your methods to align with the changes at NICE

  • Find out how evolving NICE regulations will impact pharma and how you need to adapt your methods
  • Gain clarity on what the landscape will look like from a regulatory perspective as we diverge from the European Union
  • How can we ensure that regulators are listening to industry? 

Afternoon refreshments and networking



Reducing time to market: Breaking down barriers to innovation and adoption 

  • Hear how the Accelerated Access Collaborative (AAC) is supporting rapid uptake of new products and how it differs from past initiatives
  • Learn what the AAC constitutes as innovation
  • Assess the main barriers to uptake of innovation and get first-hand information what you need to consider when selling into the NHS
  • Find out what support is in place for pharma at a national level to drive innovation at scale and pace

Dr Sam Roberts, Director of Innovation and Life Sciences, NHS England and Chief Executive, Accelerated Access Collaborative 



2020 and beyond: How long will the NHS remain a commercially viable market for pharma?

  • Learn how global regulators will be affected in a post-Brexit landscape
  • Find out what risk mitigation strategies you should put in place to prepare for Brexit implications on your business
  • Discuss whether the new Medicines and Medical Devices Bill provides postBrexit certainty for pharma
  • Will the UK remain an attractive location for skilled workers and companies to undertake research and development?

Chair’s closing remarks

Oli Hudson, Content Director, Wilmington Healthcare

By continuing to use the site you agree to our cookies policy. Accept